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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the efficacy, safety and tolerability of deep brain stimulation versus placebo, sham intervention, or best medical care,
including botulinum neurotoxin and resective/lesional surgery, in people with dystonia.
B A C K G R O U N D
Description of the condition
See Additional Table 1 for glossary of terms.
Dystonia is the third most common movement disorder, after
Parkinson’s disease and essential tremor, with an estimated overall
prevalence of 164 permillion (Steeves 2012). Dystonia syndromes
are a group of disabling, painful disorders characterised by invol-
untary sustained or intermittent muscle contractions causing ab-
normal, often repetitive, movements or postures of the face, neck,
trunk or limbs, among other muscles (Albanese 2013). Dystonic
movements are typically patterned or twisting, and are often initi-
ated or worsened by voluntary action (Albanese 2013). These neu-
rological disorders are classified according to two different axes.
Axis I is based on clinical manifestations of dystonia, and divided
into four separate dimensions: age at onset, body distribution,
temporal pattern and associated features. Age at onset classifies the
dystonia under standard age groups used for other neurological
disorders (Jinnah 2014). Body distribution includes focal dysto-
nia, segmental dystonia, multifocal dystonia, hemidystonia and
generalised dystonia (Albanese 2013; Tarsy 2006). Temporal pat-
tern classifies dystonia according to its course and type of short-
term variation (Jinnah 2014). The absence of other associated fea-
tures defines isolated dystonia, formerly known as primary dysto-
nia (Albanese 2013). Combined dystonia is defined in the pres-
ence of other neurological or systemic features and includes the
previous terms of secondary dystonia, dystonia-plus syndromes
and heredodegenerative dystonia (Jinnah 2014). Axis II is based
on the aetiology of dystonia and divided into three dimensions:
heritability, nervous system pathology, and idiopathic. In terms of
heritability, dystonia can be defined by association with heredi-
tary neurological conditions (e.g. sex-linked, autosomal or mito-
chondrial) or by having an acquired cause (Albanese 2013; Jinnah
2014; Tarsy 2006). Among the most common known causes are
drug-induced dystonia (caused by agents such as levodopa or an-
tipsychotics) and acquired lesions to the central nervous system
(CNS) such as brain injury, infections, toxins, vascular or neoplas-
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tic disorders (Calne 1988). Dystonia can also be of psychogenic
origin (i.e. functional) (Albanese 2013). The term idiopathic dys-
tonia is used when there is no acquired cause and the dystonia
remains genetically unclassified, and it can be further subclassified
into sporadic or familial idiopathic dystonia (Jinnah 2014).
The aetiology of most forms of dystonia is still not fully under-
stood, with the exception of early-onset dystonia, for which a
hereditary aetiology is common (Balint 2015). In most cases of fo-
cal adult-onset dystonia, such as cervical dystonia (the most com-
mon form of focal dystonia), the pathophysiology is generally con-
sidered to result from impaired inhibition of the CNS at multi-
ple levels resulting in abnormal sensorimotor integration (Hallett
1998).
The generalised increase in cortical and basal ganglia excitability
leads to a diminished motor function inhibition, a decrease in
spatial and temporal somatosensory discrimination and loss of
surround inhibition (incapacity to suppress adjacent regions to
activated neural circuits) (Phukan 2011; Tarsy 2006).
Description of the intervention
Deep brain stimulation (DBS) is a method of intracerebral stim-
ulation through the controlled direct application of an electrical
current to specific subcortical nuclei. It is important to note that
it is not a curative treatment. The most common neurological dis-
ease for which DBS is used is Parkinson’s disease, and the most
common target nucleus in this condition is the subthalamic nu-
cleus (Fasano 2012). In selected Parkinson’s disease patients, DBS
improves the time without dyskinesia at six months by an average
of 4.6 hours a day in participants randomised to DBS versus 0
hours in participants randomised to best medical therapy, while
also reporting a higher rate of clinically meaningful motor im-
provement, at 71% in DBS versus 32% in best medical therapy
(Weaver 2009). DBS also appears to have a higher rate of quality
of life improvement, at 64% in DBS versus 36% in best medical
therapy for Parkinson’s disease patients (Weaver 2009).
Electrical stimulation of the CNS targets is delivered through elec-
trodes that are surgically implanted and afterwards connected to
an implantable pulse generator (IPG), which is most often placed
subcutaneously in the pectoral region (Fasano 2012).
Different target nuclei for DBS have been studied in people with
dystonia, including the internal globus pallidus (GPi), the thala-
mus ventrointermediate nucleus (VIM), or the subthalamic nu-
cleus (STN), with the purpose of modulating cortical excitabil-
ity (Limousin-Dowsey 1999). In routine practice, the GPi is the
primary target for people with dystonia (Kupsch 2006; Vidailhet
2005).
Different techniques may be used, among them high or low-fre-
quency stimulation, with these having varying degrees of intensity
and effect duration (Fasano 2012; Limousin-Dowsey 1999). The
stimulation can be made with constant voltage or, more recently,
constant current, which has been suggested to improve the toler-
ance and effectiveness ofDBS (Gross 2013). Adjustments aremade
to the stimulation parameters (voltage, frequency and others) in
ambulatory follow-up examinations, to ensure optimal therapeu-
tic effects (Montuno 2013). IPGs have a limited battery life, at the
end of which a battery replacement surgery has to be conducted.
Different rechargeable (RC) IPGs have been developed to reduce
the number of battery replacement operations (Waln 2014).
How the intervention might work
There are different hypotheses concerning how DBS might work.
The inhibitory hypothesis suggests that the therapeutic efficacy
of DBS results by reducing the activity of neurons adjacent to
the stimulation lead (Filali 2004), most likely due to activation
of GABAergic afferent pathways (Chiken 2014). The excitatory
hypothesis claims that the excitation of efferent pathways and
antidromic excitation of afferent pathways results in suppression
of abnormal activity (Hashimoto 2003). Finally, the disruption
hypothesis supports the block of aberrant neural stimuli in the
cortico-basal ganglia loop, creating a dissociation between neural
afferent and efferent signals (Chiken 2015). The most plausible
mechanism is probably a combination of different effects.
Why it is important to do this review
Recent studies report the beneficial effects that DBS has in peo-
ple with certain movement disorders, including selected cases
of Parkinson’s disease and essential tremor (Flora 2010; Weaver
2009). However, no systematic review has yet examined the avail-
able literature on the outcomes of DBS in people with dystonia.
There are reports of serious events such as mood changes, cogni-
tive deficit and an increase in suicide among patients treated with
DBS for dystonia (Fasano 2012; Foncke 2006) as well as others
for patients with Parkinson’s disease, among them pulmonary em-
bolism, myocardial infarction, stroke, intracerebral haemorrhage
and infection (Fasano 2012;Weaver 2009). Therefore, uncertainty
exists regarding the risk-benefit profile of this intervention in dys-
tonia.
O B J E C T I V E S
To compare the efficacy, safety and tolerability of deep brain stim-
ulation versus placebo, sham intervention, or best medical care,
including botulinum neurotoxin and resective/lesional surgery, in
people with dystonia.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) with a parallel design, of
any duration, assessing the efficacy, safety or tolerability of deep
brain stimulation (DBS) versus placebo, a sham intervention, or
best medical treatment in people with dystonia will be eligible
for inclusion in this review. Both open and blinded trials will be
considered. We will exclude trials in which participants were their
own controls (before/after design and on/off stimulation studies)
because of the possibility of selection bias, carry-over effect and
the impossibility to isolate the lesional effect of the intervention
per se in the outcome estimate.
Types of participants
Adults (i.e. ≥ 18 years of age), in any setting, with a clinical di-
agnosis of any type of dystonia (namely primary or secondary, as
well as focal, segmental or generalised). We will adopt a pragmatic
approach to the definition of dystonia. Namely, we will consider
patients included in randomised trials with the diagnosis of dys-
tonia and in which these were evaluated on a validated and fit-for-
purpose dystonia-specific severity scale.
If studies include only a subset of the relevant participants for this
review, these will nonetheless be eligible for inclusion.
We will impose no restrictions regarding the number of partici-
pants recruited to trials, or the number of recruitment centres.
Types of interventions
We will accept any type of DBS, independent of the target-nu-
cleus, the device used or the stimulation parameters. Depending
on the data available, we will compare DBS with either: 1) the best
available pharmacological treatment, including botulinum neuro-
toxin, 2) sham stimulation, or 3) resective/lesional surgery. Sham
stimulation will have to be considered fit for purpose in order to
be included past the full-text screening stage.
Types of outcome measures
Any included study had to explicitly report at least one of the
outcomes below.
Critical outcomes
Dystonia-specific symptoms
Measured as the mean change from baseline on any validated
dystonia-specific symptomatic rating scale, measured at least one
month after DBS surgery.
Adverse events
Measured as the proportion of participants with any adverse event,
at any point during study follow-up. We will also study surgery-
related adverse events of special interest such as device infection,
electrode dislocation, central nervous system haemorrhage, stroke,
and death, measured at any point during study follow-up. Addi-
tionally, we will look specifically for stimulation-related adverse
events of special interest, such as dysarthria, dyskinesia, loss of de-
sired effect, and suicide attempts, measured at any point during
study follow-up. Finally, we will aim to study the proportions of
participants with specific adverse events, measured at any point
during study follow-up.
Important outcomes
Subjective evaluation of clinical status
This outcome may be evaluated by both patients and clinicians, as
assessed with validated assessment tools such as Patient Subjective
Assessment of Change, Patient Global Assessment of Improve-
ment, Patient Evaluation of Global Response (PEGR), Patient and
Physician Global Assessment of Change, Investigator Global As-
sessment of Efficacy (IGAE), and Physician Global Assessment of
Change (PGAC), and Visual analogue scale (VAS) for symptom
severity,measured at least onemonth afterDBS surgery. Subjective
evaluation of clinical status will be dichotomised into patients that
reported improvement or where classified by clinicians as having
improved, and patients without improvement.
Quality of life
Changes in quality-of-life assessments, as assessed with validated
assessment tools such as Short Form 36 (SF-36) Quality-of-Life
questionnaire, measured at any point during study follow-up.
Functional capacity
As assessed using a validated assessment tool, such as the disability
domain of Toronto Western Spasmodic Torticollis Rating Scale,
measured at any point during study follow-up. We will also seek
to study the proportions of participants who are able to perform
selected activities of daily living, such as working capabilities and
the ability to drive a car,measured at any point during study follow-
up.
Emotional state
As assessed by validated scales such as the Beck Depression Inven-
tory, Brief Psychiatric Rating Scale, measured at any point during
study follow-up.
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Tolerability
As assessed by the proportion of participants that withdraw from
the study or alternatively interrupted DBS due to adverse events,
measured at any point during study follow-up.
Search methods for identification of studies
Electronic searches
We intent to search the following databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; latest issue) in the Cochrane Library.
2. MEDLINE Ovid (from 1993 to present).
3. Embase Ovid(from 1993 to present).
4. Web of Science (from 1993 to present).
5. SciELO (Scientific Electronic Library Online; from 1993 to
present).
6. LILACS (Latin American and Caribbean Health Science
Information database; from 1993 to present).
We will assess non-English language papers equally, translating
them as necessary and evaluating them for inclusion.
For the identification of studies considered for inclusion in this
review, we developed detailed search strategies for each database
searched. Please see Appendix 1 for theCENTRAL search strategy,
Appendix 2 for the MEDLINE search strategy, and Appendix 3
for the Embase search strategy.
We intent to run all electronic searches from 1993, the first year
DBS was reported in any condition.
Searching other resources
We intent to search the following clinical trial registries.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. EU Clinical Trials Register (www.clinicaltrialsregister.eu;
from 1995).
3. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
4. ISRCTN Registry (www.isrctn.com; from 2000).
We intent to search the grey literature via the following databases.
1. OpenSIGLE (from 1993).
2. Database of Abstracts of Reviews of Effects (DARE).
3. British Library Thesis Service.
4. National Technical Information Service (NTIS).
We considered conducting a handsearch of abstracts of the follow-
ing international congresses of movement disorders:
1. American Academy of Neurology (from 1993);
2. European Academy of Neurology;
3. European Neurological Society (up till 2013);
4. European Federation of Neurological Science (up till 2013);
5. Movement Disorders Society;
6. International Association of Parkinsonism and Related
Disorders.
However, owing to the fact that all the conference proceedings
are published in indexed journals, at least since 1993, we have
opted against conducting a handsearch since we do not expect that
further citations will be found.
We will cross-check the reference lists of both selected and poten-
tially eligible studies for additional studies to be included. We will
translate non-English reports. Whenever necessary, we will con-
tact study authors and DBS device companies for further access
to data.
Data collection and analysis
Selection of studies
Two review authors will independently and in duplicate screened
all titles and abstracts identified from searches to determine which
meet the inclusion criteria. We will retrieve in full text any papers
identified as potentially relevant by at least one author or those
without an available abstract. Two review authors will indepen-
dently screen full-text articles, with discrepancies resolved by dis-
cussion and by consulting a third author where necessary to reach
consensus.We will collate duplicate publications and present these
by individual study. The screening and selection process will be
outlined in a PRISMA flow chart (Liberati 2009).
Data extraction and management
Two review authors will independently extract study data onto
pre-piloted, standardised forms, after which we will cross-check
the forms for accuracy. We will use the Covidence platform for
this purpose (Covidence 2016). We will resolve disagreements by
discussion or, if necessary, arbitration by a third review author. We
will extract the following data from each study.
1. Participants: method for referral, inclusion and exclusion
criteria, demographics and clinical baseline characteristics,
number and reasons for withdrawals, exclusions and loss to
follow-up, if any.
2. Interventions: full description of intervention, duration of
treatment period and follow-up, providers, and co-interventions,
if any.
3. Comparisons: number of randomised participants to each
arm, compliance and dropouts, reasons for dropouts, and ability
to perform an intention-to-treat analysis.
4. Outcomes: definition of outcomes, use of validated
measurement tools, time-point measurements, change from
baseline or post-interventional measures, and missing outcomes,
if any.
5. Study design: interventional, randomised, controlled,
double-blind.
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Assessment of risk of bias in included studies
We will assess the risk of bias of included studies according to the
domains described in the Cochrane tool for assessing risk of bias
(Higgins 2011a), and classify the risk of bias for each domain as
high, unclear, or low, and the overall assessment as high or low.
We will assess two further domains, which are described below:
’for-profit bias’ and ’prospective clinical trial registration’. We will
use the following definitions for each domain in the risk of bias
assessment.
Random sequence generation
• Low risk of bias: the study performed sequence generation
using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were adequate if an independent person not
otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not report the
sequence generation method.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: participants and investigators enrolling
participants could not foresee assignment because one of the
following, or an equivalent method, was used to conceal
allocation: central allocation, sequentially numbered drug
containers of identical appearance; sequentially numbered,
opaque, sealed envelopes.
• Unclear risk of bias: insufficient information to permit
judgement of ’low risk’ or ’high risk’.
• High risk of bias: participants or investigators enrolling
participants could possibly foresee assignments and thus
introduce selection bias.
In addition to these criteria, we will consider the implications of
baseline imbalances in prognostic factors affecting the trial out-
comes, as these may lead to selection bias (Corbett 2014).
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judge that the
outcome is not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
is unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that the blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
We will consider blinding separately for different outcomes, as
appropriate.
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement is likely to
be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported the following predefined
outcomes. If the original trial protocol was available, the
outcomes were called for in that protocol. If the trial protocol
was obtained from a trial registry, the outcomes sought should
have been those enumerated in the original protocol if the trial
protocol was registered before or at the time that the trial was
begun. If the trial protocol was registered after the trial was
begun, we did not consider those outcomes to be reliable.
• Unclear risk: the study authors do not report all predefined
outcomes fully, or it is unclear whether the study authors
recorded data on these outcomes or not.
• High risk: the study authors do not report one or more
predefined outcomes.
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For-profit bias
In order to assess the study source of funding, this domain was
added in place of the ’other bias’ domain.
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or trial results.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as the trial does not provide any information on
clinical trial support or sponsorship.
• High risk of bias: the trial is sponsored by industry or
received other type of for-profit support.
Prospective clinical trial registration
• Low risk of bias: a trial protocol is available, and was
published before the start of the trial.
• Unclear risk of bias: insufficient information to permit
judgement of ’low risk’ or ’high risk’.
• High risk of bias: no trial protocol is available or the trial
was registered after it had already begun.
Measures of treatment effect
Whenever possible, we will extract continuous outcomes. These
data will then be pooled from the studies, where adequate, and
used for comparison.
Dichotomous data
We will analyse these data based on the number of events and the
number of people assessed in the intervention and comparison
groups. We will use these to calculate the risk ratio (RR) and 95%
confidence interval (CI).
Continuous data
We will analyse these data based on the mean, standard deviation
(SD) and number of people assessed for both the intervention and
comparison groups to calculate mean difference (MD) and 95%
CI. Where the MD is reported without individual group data, we
will use this to report the study results. If more than one study
measures the same outcome using different validated tools, we will
calculate a standardised mean difference (SMD), namely Hedges’
(adjusted) g (Hedges 1985), and 95% CI. For interpretation of
effect sizes with SMDs, we will use a rule of thumb to define a
small effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a
large effect (SMD = 0.8) (Cohen 1988). If necessary for compar-
ison, we will dichotomised rating scales using each study author’s
own criteria for improvement or no improvement. If these criteria
are not described, we will define ’improvement’ as any beneficial
change from baseline, and ’no improvement’ as lack of improve-
ment or any deterioration from baseline.
Unit of analysis issues
The primary data of analysis in the included studies should be
individual trial participants.
We will examine data from parallel-group RCTs and will prefer-
entially use data from intention-to-treat analyses.
If data are presented at different periods of follow-up,wewill report
the same outcome separately each time it is presented, based on
the different periods of follow-up being reported. If the number
of studies cannot adequately populate such subgroups, we will opt
to select the longest period of follow-up for each study.
In case studies included multiple active DBS arms, we will com-
bine all arms into a single pair-wise comparison, using the Re-
viewManager (RevMan) 5.3 calculator (RevMan 2014), using the
methods suggested by Cochrane (Higgins 2011c).
Given that individual participants are liable to experience an ad-
verse event more than once, and adverse events may be reported as
such, we will preferentially request data from study authors con-
cerning the number of participants with adverse events. If this ap-
proach is not successful we will treat adverse events not as categor-
ical data (did or did not experience the event), but rather, as count
data. Thus, we will consider not only if the data were reported, but
howmany times they were reported. In such cases we will treat the
adverse events as Poisson data, and will preferentially summarise
the data as rate ratios, standardised to a given time period, to be
defined post-hoc.
Dealing with missing data
For missing outcome or summary data we will use imputation
methods to derive themissing data (where possible) and report any
assumptions in the review. All cases will be investigated, through
sensitivity analyses, regarding the effects of any imputed data on
pooled effect estimates.
As a first option we will choose to use the available information
(e.g. standard error (SE), 95% CI or exact P value) to algebraically
recover the missing data (Higgins 2011b; Higgins 2011c; Wiebe
2006). When change from baseline SD are not reported or not
possible to extract wewill attempt to create a correlation coefficient
based on another study in this review, and then use this correlation
coefficient to impute a change from baseline SD (Abrams 2005;
Follmann 1992; Higgins 2011c).
If this is to fail, and if at least one sufficiently large and similar
study were to exist, we will use a method of single imputation
(Furukawa 2006; Higgins 2011c).
Lastly, if a sufficient number of included studies with complete
information is to exist, we will use multiple imputation methods
to derive missing data (Carpenter 2013; Rubin 1991).
If none of these methods are successful we will conduct a narrative
synthesis for the data in question.
In case relevant data are only reported through figures or graphs,
two authors will independently extract the relevant information.
Wewill only use the data if the two extractions give the same result.
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Assessment of heterogeneity
Where data are pooled using meta-analysis, we will assess the de-
gree of heterogeneity by visual inspection of forest plots and by
examining the Chi2 test for heterogeneity. We will quantify het-
erogeneity using the I2 statistic. We will consider an I2 value of
50% or more to represent substantial levels of heterogeneity, but
interpret this value in light of the size and direction of effects and
the strength of the evidence for heterogeneity, based on the P value
from the Chi2 test (Higgins 2003). Where heterogeneity is found
in pooled effect estimates, we will explore possible reasons for vari-
ability by conducting subgroup and sensitivity analyses.
Assessment of reporting biases
We intend to assess publication bias through visual inspection of
funnel plot asymmetry (Sterne 2001) and Peters’ regression tests
(Peters 2006), provided that 10 or more studies per outcome are
available (Sterne 2011).
Data synthesis
We will perform statistical analysis using Review Manager
(RevMan) version 5.3 (RevMan 2014), Stata version 14 (Stata
2015) and Trial Sequential Analysis (TSA) (Thorlund 2011; TSA
2011) software.
Meta-analysis
We intent to pool effectmeasures by applying theMantel-Haenszel
method for dichotomous outcomes, the inverse-variance method
for continuous, rate ratio and count data syntheses, if required.
We will conduct data synthesis using a random-effects model by
default independently of the presence or not of considerable sta-
tistical heterogeneity owing to the variety of disease subtypes that
we intent to analyse. We will present all results with 95% CI.
We intend to calculate the number of participants needed to treat
for an additional beneficial outcome (NNTB) and for an addi-
tional harmful outcome (NNTH) from meta-analysis estimates,
rather than treating data as if they came from a single trial, as the
latter approach is more prone to bias, especially when there are
significant imbalances between groups within one or more trials
in the meta-analysis (Altman 2002). However, caution is needed
in interpreting these findings since they may be misleading be-
cause of variation in the event rates in each trial, differences in the
outcomes considered, effects of secular trends on disease risk, and
differences in clinical setting (Smeeth 1999).
Where data from the study reports could not be combined into a
meta-analysis, we will present a qualitative summary of the study
results in the review text.
Trial sequential analysis
In order to explore whether the cumulative data were adequately
powered to evaluate the critical outcomes of this review, we intend
to perform a trial sequential analysis (Wetterslev 2008), and calcu-
late a required information size (also known as the ’heterogeneity-
adjusted required information size’) (Wetterslev 2009). Trial se-
quential analysis aims to evaluate whether statistically significant
results of meta-analysis are reliable by accounting for the required
information size (i.e. the number of participants in the meta-anal-
ysis required to accept or reject an intervention effect). The tech-
nique is analogous to sequential monitoring boundaries in single
trials. Trial sequential analysis adjusts the threshold of statistical
significance and has been shown to reduce the risk of random
errors due to repetitive testing of accumulating data (Imberger
2016).
We intend to calculate the required information size and com-
pute the trial sequential monitoring boundaries using theO’Brien-
Fleming approach (O’Brien 1979). The required information size
will be based on the event proportion or standard deviation in the
control group; assumption of a plausible relative risk reduction
(RRR) of 20%; a 5% risk of type I error; a 20% risk of type II
error (power = 80%); and the observed heterogeneity of the meta-
analysis (Jakobsen 2014; Wetterslev 2009).
Assessment of confidence in cumulative evidence
As recommended by the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) Working Group
methodology (Atkins 2004), two review authors will indepen-
dently assess all of the outcomes in the following domains: risk
of bias, inconsistency, indirectness, imprecision and publication
bias. In case of disagreement the authors will meet to reach con-
sensus, consulting an independent third review author if nec-
essary. For this purpose, we will use GRADEproGDT software
(GRADEproGDT2014), whichwewill then extract into the form
of a ’Summary of findings’ table for inclusion into the review
manuscript.
To ensure the consistency and reproducibility of GRADE judge-
ments, we will apply the following criteria to each domain for all
key comparisons of the critical outcomes.
• Study limitations: downgrade once if more than 30% of
participants were from studies classified as being at a high risk of
bias across any domain.
• Inconsistency: downgrade once if heterogeneity is
statistically significant or if the I2 value is more than 40%. When
a meta-analysis was not performed we will downgrade once if
trials did not show effects in the same direction.
• Indirectness: downgrade once if more than 50% of the
participants were outside the target group.
• Imprecision: downgrade once if the optimal information
size criterion is not met or, alternatively, if it is met but the 95%
7Deep brain stimulation for dystonia (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CI fails to exclude important benefit or important harm (Guyatt
2011).
• Publication bias: downgrade once where there is direct
evidence of publication bias or if estimates of effect are based on
small scale, industry-sponsored studies raising a high index of
suspicion of publication bias.
We will apply the following definitions of the quality of evidence
(Balshem 2011)
• .High quality: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate quality: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low quality: our confidence in the effect estimate is
limited; the true effect may be substantially different from the
estimate of the effect.
• Very low quality: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
The list of outcomes we intend to include in the GRADE analysis
are the following.
• Dystonia-specific symptoms.
• Proportion of participants with adverse events.
• Subjective evaluation of clinical status.
• Quality-of-life assessment.
• Functional capacity.
• Emotional state.
• Tolerability.
’Summary of findings’ table
As has become standard practice in Cochrane reviews, we will
include a ’Summary of findings’ table to present the main findings
of this review in a simple tabular format. In particular, we will
include key information concerning the quality of evidence, the
magnitude of effect of the interventions examined, and the sum
of available data on the available outcomes.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses have been planned for the following areas.
1. Disease subtypes (i.e. generalised and non-generalised
dystonia; primary and secondary dystonia).
2. Target-nucleus (i.e. internal globus pallidus (GPi), thalamus
ventrointermediate nucleus (VIM) and subthalamic nucleus
(STN).
3. Stimulation parameters (i.e. constant current and constant
voltage).
4. Risk of bias (i.e low, high and unclear).
5. Control intervention used (i.e. botulinum treatment and
lesional surgery; placebo and sham intervention).
Sensitivity analysis
We will conduct sensitivity analyses by excluding studies in which
imputation methods were applied as well as studies assessed as
being at high risk of bias in order to evaluate the robustness of our
results.
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Deep brain stimulation Neurosurgical procedure whereby an electric current delivered by electrodes placed in the deep brain
stimulate target nuclei
Target nucleus/nuclei Groups of neuronal cell bodies, located in the deep areas of the brain, aimed to be stimulated by deep
brain stimulation
Dystonia Common movement disorder in which people have abnormal torsion movements or postures of one or
more body segments, such as the neck or a limb, that they cannot control. It is frequently accompanied
by social embarrassment and pain
Primary dystonia Dystonic disorder caused by an intrinsic basal ganglia problem unrelated to any other disease. It is
sometimes caused by mutation and dystonia is the main clinical manifestation in the majority of primary
dystonias
Secondary dystonia Dystonic disorder caused by another disease (i.e. caused by stroke)
Generalised dystonia Dystonia affecting all body segments (i.e. trunk, upper and lower limbs)
Cervical dystonia Dystonia affecting the neck
Blepharospasm Dystonia affecting the eye lids
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. MeSH descriptor: [Dystonia] explode all trees
2. dystonia
3. MeSH descriptor: [Dystonic Disorders] explode all trees
4. dystonic disorder
5. MeSH descriptor: [Blepharospasm] explode all trees
6. blepharospasm
7. MeSH descriptor: [Meige Syndrome] explode all trees
8. Meige syndrome
9. MeSH descriptor: [Torticollis] explode all trees
10. torticollis
11. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
12. MeSH descriptor: [Deep Brain Stimulation] explode all trees
13. deep brain stimulation
14. MeSH descriptor: [Electric Stimulation] explode all trees
15. electric stimulation
16. #12 or #13 or #14 or #15
17. #11 and #16 in Trial
Appendix 2. MEDLINE search strategy
1. “randomized controlled trial”.pt.
2. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
3. (retraction of publication or retracted publication).pt.
4. or/1-3
5. (animals not humans).sh.
6. ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal correspondence) not “randomized
controlled trial”).pt.
7. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not “randomized controlled
trial”.pt.
8. or/5-7
9. 4 not 8 (728284)10 exp Deep Brain Stimulation/
10. (stimulat* or stimuli* or stimulu*).ab,ti.
11. DBS.ab,ti.
12. exp Dystonic Disorders/
13. dyston*.ab,ti.
14. exp dystonia/
15. or/10-12
16. or/13-15
17. and/9,16-17
18. remove duplicates from 18
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Appendix 3. Embase search strategy
1. exp Deep Brain Stimulation/
2. (stimulat* or stimuli* or stimulu*).ab,ti.
3. DBS.ab,ti.
4. exp Dystonic Disorders/
5. dyston*.ab,ti.
6. exp dystonia/
7. or/1-3
8. or/4-6
9. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
10. RETRACTED ARTICLE/
11. or/9-10
12. (animal$ not human$).sh,hw.
13. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
14. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized
controlled trial/
15. or/12-14
16. 11 not 15
17. and/7-8,16
18. limit 17 to embase
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